PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
CONCLUSION: The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI. The increased PFS seen with the addition of avelumab warrants further investigation in this patient population.PMID:38513188 | DOI:10.1200/JCO.23.01940 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Erica L Mayer Yue Ren Nikhil Wagle Reshma Mahtani Cynthia Ma Angela DeMichele Massimo Cristofanilli Jane Meisel Kathy D Miller Yara Abdou Elizabeth C Riley Rubina Qamar Priyanka Sharma Sonya Reid Natalie Sinclair Meredith Faggen Caroline C Block Naomi Ko Source Type: research
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
CONCLUSION: The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI. The increased PFS seen with the addition of avelumab warrants further investigation in this patient population.PMID:38513188 | DOI:10.1200/JCO.23.01940 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Erica L Mayer Yue Ren Nikhil Wagle Reshma Mahtani Cynthia Ma Angela DeMichele Massimo Cristofanilli Jane Meisel Kathy D Miller Yara Abdou Elizabeth C Riley Rubina Qamar Priyanka Sharma Sonya Reid Natalie Sinclair Meredith Faggen Caroline C Block Naomi Ko Source Type: research
Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism
J Nanobiotechnology. 2024 Mar 19;22(1):122. doi: 10.1186/s12951-024-02356-0.ABSTRACTEndocrine therapy is standard for hormone receptor-positive (HR+) breast cancer treatment. However, current strategies targeting estrogen signaling pay little attention to estradiol metabolism in the liver and is usually challenged by treatment failure. In a previous study, we demonstrated that the natural compound naringenin (NAR) inhibited HR+ breast cancer growth by activating estrogen sulfotransferase (EST) expression in the liver. Nevertheless, the poor water solubility, low bio-barrier permeability, and non-specific distribution limit...
Source: Cancer Control - March 20, 2024 Category: Cancer & Oncology Authors: Yuying Zhao Hanxu Tan Juping Zhang Dandan Zhan Bowen Yang Shicui Hong Bo Pan Neng Wang Tongkai Chen Yafei Shi Zhiyu Wang Source Type: research
Efficacy of Nursing Interventions Using Motivational Interviewing Aimed at Weight Loss in Overweight/Obese Breast Cancer Patients Undergoing Endocrine Therapy
CONCLUSIONS: Nursing-administered MI did not achieve the goal of 5% weight loss at week 12. However, it increased physical activity and reduced sedentary time, showing potential for promoting healthier habits.PMID:38509012 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Emi Sato Masako Shomura Mari Mizuno Kozue Yokoyama Mayako Terao Banri Tsuda Toru Hanamura Takuho Okamura Kota Fukai Naoki Niikura Source Type: research
Efficacy of Nursing Interventions Using Motivational Interviewing Aimed at Weight Loss in Overweight/Obese Breast Cancer Patients Undergoing Endocrine Therapy
CONCLUSIONS: Nursing-administered MI did not achieve the goal of 5% weight loss at week 12. However, it increased physical activity and reduced sedentary time, showing potential for promoting healthier habits.PMID:38509012 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Emi Sato Masako Shomura Mari Mizuno Kozue Yokoyama Mayako Terao Banri Tsuda Toru Hanamura Takuho Okamura Kota Fukai Naoki Niikura Source Type: research
A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients
Clin Pharmacol Ther. 2024 Mar 19. doi: 10.1002/cpt.3255. Online ahead of print.ABSTRACTTamoxifen is part of the standard of care of endocrine therapy for adjuvant treatment of breast cancer. However, survival outcomes with tamoxifen are highly variable. The concentration of endoxifen, the 30-100 times more potent metabolite of tamoxifen and bioactivated by the CYP2D6 enzyme, has been described as the most relevant metabolite of tamoxifen metabolism. A genome-wide association study (GWAS) was performed with the objective to identify genetic polymorphisms associated with endoxifen serum concentration levels and clinical outc...
Source: Clinical Breast Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Anabel Beatriz Sanchez-Spitman Stefan B öhringer Vincent Olaf Dezentj é Hans Gelderblom Jesse Joachim Swen Henk-Jan Guchelaar Source Type: research
A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients
Clin Pharmacol Ther. 2024 Mar 19. doi: 10.1002/cpt.3255. Online ahead of print.ABSTRACTTamoxifen is part of the standard of care of endocrine therapy for adjuvant treatment of breast cancer. However, survival outcomes with tamoxifen are highly variable. The concentration of endoxifen, the 30-100 times more potent metabolite of tamoxifen and bioactivated by the CYP2D6 enzyme, has been described as the most relevant metabolite of tamoxifen metabolism. A genome-wide association study (GWAS) was performed with the objective to identify genetic polymorphisms associated with endoxifen serum concentration levels and clinical outc...
Source: Clinical Genitourinary Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Anabel Beatriz Sanchez-Spitman Stefan B öhringer Vincent Olaf Dezentj é Hans Gelderblom Jesse Joachim Swen Henk-Jan Guchelaar Source Type: research
A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients
Clin Pharmacol Ther. 2024 Mar 19. doi: 10.1002/cpt.3255. Online ahead of print.ABSTRACTTamoxifen is part of the standard of care of endocrine therapy for adjuvant treatment of breast cancer. However, survival outcomes with tamoxifen are highly variable. The concentration of endoxifen, the 30-100 times more potent metabolite of tamoxifen and bioactivated by the CYP2D6 enzyme, has been described as the most relevant metabolite of tamoxifen metabolism. A genome-wide association study (GWAS) was performed with the objective to identify genetic polymorphisms associated with endoxifen serum concentration levels and clinical outc...
Source: Clinical Pharmacology and Therapeutics - March 19, 2024 Category: Drugs & Pharmacology Authors: Anabel Beatriz Sanchez-Spitman Stefan B öhringer Vincent Olaf Dezentj é Hans Gelderblom Jesse Joachim Swen Henk-Jan Guchelaar Source Type: research
Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism
Endocrine therapy is standard for hormone receptor –positive (HR+) breast cancer treatment. However, current strategies targeting estrogen signaling pay little attention to estradiol metabolism in the liver and is... (Source: Journal of Nanobiotechnology)
Source: Journal of Nanobiotechnology - March 19, 2024 Category: Nanotechnology Authors: Yuying Zhao, Hanxu Tan, Juping Zhang, Dandan Zhan, Bowen Yang, Shicui Hong, Bo Pan, Neng Wang, Tongkai Chen, Yafei Shi and Zhiyu Wang Tags: Research Source Type: research
Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer
Estrogen receptor positive (ER+) breast cancer is the most common breast cancer diagnosed annually in the US with endocrine-based therapy as standard-of-care for this breast cancer subtype. Endocrine therapy includes treatment with antiestrogens, such as selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and aromatase inhibitors (AIs). Despite the appreciable remission achievable with these treatments, a substantial cohort of women will experience primary tumor recurrence, subsequent metastasis, and eventual death due to their disease. In these cases, the breast cancer cells...
Source: Frontiers in Endocrinology - March 18, 2024 Category: Endocrinology Source Type: research
Towards clinical adherence monitoring of oral endocrine breast cancer therapies by LC-HRMS-method development, validation, comparison of four sample matrices, and proof of concept
Anal Bioanal Chem. 2024 Mar 15. doi: 10.1007/s00216-024-05244-6. Online ahead of print.ABSTRACTOral endocrine therapies (OET) for breast cancer treatment need to be taken over a long period of time and are associated with considerable side effects. Therefore, adherence to OET is an important issue and of high clinical significance for breast cancer patients' caregivers. We hypothesized that a new bioanalytical strategy based on liquid chromatography and high-resolution mass spectrometry might be suitable for unbiased adherence monitoring (AM) of OET. Four different biomatrices (plasma, urine, finger prick blood by volumetr...
Source: Analytical and Bioanalytical Chemistry - March 15, 2024 Category: Chemistry Authors: Cathy M Jacobs Julia C Radosa Lea Wagmann Julia S M Zimmermann Askin C Kaya Aylin Ayg ün Tatjana Edel Lisa Stotz Mohamed Ismaeil Erich-Franz Solomayer Markus R Meyer Source Type: research
Impact of HER2 ‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study
ConclusionThis study suggested that HER2-low expression may predict the efficacy of ET but not that of CDK4/6 inhibitor plus ET in HR-positive/HER2-negative MBC patients. The results of this study highlight the importance of integrating HER2 status in tailoring personalized treatment strategies for HR-positive MBC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 14, 2024 Category: Cancer & Oncology Authors: Yun Wu,
Hongnan Mo,
Hangcheng Xu,
Yan Wang,
Jiayu Wang,
Fei Ma,
Binghe Xu Tags: ORIGINAL ARTICLE Source Type: research
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors and beyond
Expert Rev Anticancer Ther. 2024 Mar 12. doi: 10.1080/14737140.2024.2330601. Online ahead of print.ABSTRACTINTRODUCTION: Chemotherapy has been traditionally used as neo-adjuvant therapy in breast cancer for down-staging of locally advanced disease in all sub-types. In the adjuvant setting, genomic assays have shown that a significant proportion of ER positive/HER2 negative patients do not derive benefit from the addition of chemotherapy to adjuvant endocrine therapy. An interest in hormonal treatments as neo-adjuvant therapies in ER positive/HER2 negative cancers has been borne by their documented success in the adjuvant s...
Source: Expert Review of Anticancer Therapy - March 13, 2024 Category: Cancer & Oncology Authors: Athina Stravodimou Ioannis A Voutsadakis Source Type: research
